ATE432293T1 - Antikörper gegen tenascin-c - Google Patents

Antikörper gegen tenascin-c

Info

Publication number
ATE432293T1
ATE432293T1 AT05813654T AT05813654T ATE432293T1 AT E432293 T1 ATE432293 T1 AT E432293T1 AT 05813654 T AT05813654 T AT 05813654T AT 05813654 T AT05813654 T AT 05813654T AT E432293 T1 ATE432293 T1 AT E432293T1
Authority
AT
Austria
Prior art keywords
tenascin
domain
specific binding
binding members
antibodies
Prior art date
Application number
AT05813654T
Other languages
English (en)
Inventor
Simon Brack
Michela Silacci
Dario Neri
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of ATE432293T1 publication Critical patent/ATE432293T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05813654T 2004-11-09 2005-10-31 Antikörper gegen tenascin-c ATE432293T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62617304P 2004-11-09 2004-11-09
US67737605P 2005-05-03 2005-05-03
PCT/EP2005/011624 WO2006050834A2 (en) 2004-11-09 2005-10-31 Antibodies against tenascin-c

Publications (1)

Publication Number Publication Date
ATE432293T1 true ATE432293T1 (de) 2009-06-15

Family

ID=36336853

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05813654T ATE432293T1 (de) 2004-11-09 2005-10-31 Antikörper gegen tenascin-c

Country Status (19)

Country Link
US (1) US7968685B2 (de)
EP (2) EP2157102A1 (de)
JP (2) JP2008518609A (de)
KR (1) KR20070085892A (de)
CN (1) CN101090913B (de)
AT (1) ATE432293T1 (de)
AU (1) AU2005304031B2 (de)
BR (1) BRPI0517967B8 (de)
CA (1) CA2586661A1 (de)
CY (1) CY1110481T1 (de)
DE (1) DE602005014665D1 (de)
DK (1) DK1817345T3 (de)
EA (1) EA013537B1 (de)
ES (1) ES2327349T3 (de)
MX (1) MX2007005582A (de)
PL (1) PL1817345T3 (de)
PT (1) PT1817345E (de)
SI (1) SI1817345T1 (de)
WO (1) WO2006050834A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
EP1957531B1 (de) * 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
CA2682851C (en) 2007-04-02 2017-01-17 Philogen S.P.A. A novel antigen associated with the neovasculature of tumour metastases
BRPI0812924A2 (pt) * 2007-06-28 2014-12-09 Philogen Spa Imunocitocinas para o tratamento de câncer em combinação com agentes quimioterapêuticos
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
EP2209805B1 (de) 2007-10-30 2017-09-06 Philogen S.p.A. Mit rheumatoider arthritis assoziiertes antigen
WO2009089998A1 (en) * 2008-01-15 2009-07-23 Philochem Ag Binding members for tenascin-c domain a2
WO2010078916A1 (en) 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
EP2379116B1 (de) 2009-01-07 2015-08-26 Philogen S.p.A. Mit endometriose assoziierte antigene
WO2011001276A1 (en) 2009-06-30 2011-01-06 Philogen S.P.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
US20130004519A1 (en) * 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
BR112013002444A2 (pt) * 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
US9549981B2 (en) 2011-07-19 2017-01-24 Philogen S.P.A. Sequential antibody therapy
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
JP6241912B2 (ja) * 2012-04-27 2017-12-06 国立研究開発法人量子科学技術研究開発機構 核医学診断装置の制御方法、核医学診断装置、および診断剤キット
EP2903629B1 (de) 2012-10-03 2019-07-10 Philogen S.p.A. Antikörperkonjugat zur verwendung bei der behandlung von entzündlichen darmerkrankungen
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
WO2015114166A2 (en) * 2014-02-03 2015-08-06 Philochem Ag Targeted drug conjugates
EP3193940A1 (de) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepine und konjugate daraus
US10647760B2 (en) 2015-12-11 2020-05-12 Philogen S.P.A. Antibodies for treatment and diagnosis of inflammatory bowel disease
EP3443003B1 (de) 2016-04-15 2020-12-30 Philogen S.p.A. Nicht-glykosylierter anti-tenascin-antikörper
JP7089483B2 (ja) * 2016-05-11 2022-06-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 修飾された抗テネイシン抗体及び使用方法
EP3455254B1 (de) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und einem tenascin-bindungsteil
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
US11103592B2 (en) 2016-11-09 2021-08-31 Philogen S.P.A. IL2 and TNF mutant immunoconjugates
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
EP3634999A1 (de) 2017-06-07 2020-04-15 Philogen S.p.A. Gefässendothelwachstumsfaktor-/antifibronectin-antikörper-fusionsproteine
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
TW202016144A (zh) * 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
EP3660039A1 (de) 2018-11-30 2020-06-03 Philogen S.p.A. Il2-immunkonjugate
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
US12583888B2 (en) 2019-02-04 2026-03-24 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
US20230055143A1 (en) * 2019-12-20 2023-02-23 Medimmune, Llc Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3
WO2022073038A1 (en) 2020-10-02 2022-04-07 Abbvie Inc. Interleukin-22 (il-22) fusion proteins and uses thereof
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
IT1307864B1 (it) * 1999-04-20 2001-11-19 Istituto Naz Per La Ricerca Su Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
EP1259548A1 (de) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antikörper gegen die ed-b domäne von fibronektin, konjugate die diesen antikörper enthalten, und deren verwendung zum nachweis und zur behandlung von angiogenese
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
CY1110481T1 (el) 2015-04-29
AU2005304031A1 (en) 2006-05-18
BRPI0517967A (pt) 2008-10-28
JP2008518609A (ja) 2008-06-05
MX2007005582A (es) 2007-09-11
HK1115756A1 (zh) 2008-12-05
EA013537B1 (ru) 2010-06-30
ES2327349T3 (es) 2009-10-28
JP2012176957A (ja) 2012-09-13
EP1817345B1 (de) 2009-05-27
EA200700991A1 (ru) 2007-12-28
US7968685B2 (en) 2011-06-28
KR20070085892A (ko) 2007-08-27
WO2006050834A3 (en) 2007-02-08
PL1817345T3 (pl) 2009-10-30
CN101090913A (zh) 2007-12-19
DE602005014665D1 (de) 2009-07-09
EP2157102A1 (de) 2010-02-24
DK1817345T3 (da) 2009-09-28
CN101090913B (zh) 2015-11-25
CA2586661A1 (en) 2006-05-18
PT1817345E (pt) 2009-08-21
WO2006050834A2 (en) 2006-05-18
US20080056997A1 (en) 2008-03-06
JP5127085B2 (ja) 2013-01-23
EP1817345B9 (de) 2009-11-18
AU2005304031B2 (en) 2009-04-23
SI1817345T1 (sl) 2009-10-31
BRPI0517967B1 (pt) 2020-09-15
BRPI0517967B8 (pt) 2021-05-25
EP1817345A2 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
CY1110481T1 (el) Αντισωματα εναντι τενασκινης-c
DE602006016344D1 (de) Für das fibroblastenaktivierungsprotein spezifische antikörpermoleküle und immunkonjugate, die diese enthalten
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
CY1119102T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεισαυτων
ATE505544T1 (de) Monoklonale antikörper und einzelkettenantikörper fragments gegen das zelloberflächen prostataspezifische membranantigen
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
MX2007001338A (es) Anticuerpos antagonistas de il-17.
ATE530195T1 (de) Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA200801172A1 (ru) Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
CY2022028I2 (el) Εξανθρωπισμενα αντισωματα αντι-cd19 και οι χρησεις τους στην θεραπεια ογκων, μεταμοσχευσης και ασθενειων αυτο-ανοσιας
BRPI0918555A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de um tumor maligno em um animal, e, uso da composição.
AR069747A1 (es) Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion
BRPI0818780A2 (pt) Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos
WO2008065378A3 (en) Binding members for interleukin-6
IL172871A (en) Isolated human antibody or antigen-binding fragment thereof, an immunoconjugate, a single chain antibody molecule and a polypeptide comprising the same and uses thereof
SI2993187T1 (sl) Protitelesa, usmerjena proti HER-3, in njihove uporabe
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
CY1121294T1 (el) Αντι-ilt7 αντισωμα
BRPI0918739A2 (pt) anticorpo, composição, molécula de ácido nucleico, método de tratamento de tumor maligno em animais, e, uso da composição.
EP2631248A3 (de) Behandlung von Tumoren unter Verwendung eines spezifischen Anti-L1-Antikörpers
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EP2192132A3 (de) Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1817345

Country of ref document: EP